TUBERKULEZ VA QANDLI DIABET BILAN KOMORBID HOLATDA TUR VA TUBERKULEZ BILAN BEMORLARDA IMMUNOLOGIK VA SITOKINLAR PROFILI MARKERLARINING PROGNOSTIK IMKONIYATLARINI ANIQLASH

Authors

DOI:

https://doi.org/10.5281/zenodo.23101760

Keywords:

tuberkulyoz, 2-tur qandli diabet, interleykin, o‘sma nekrozi omili, komorbid

Abstract

Mycobacterium tuberculosis ga qarshi immun javob reaksiyalarini muvofiqlashtirish hamda hujayralararo kooperatsiyani ta’minlash bevosita sitokinlar tizimining funksional faolligi bilan belgilanadi. Tuberkulyoz infeksiyasida samarali himoya immuniteti Th1-tipidagi sitokinlar profilining mutanosib sinteziga bog‘liq bo‘lib, jarayonga qandli diabet kabi tizimli metabolik kasallikning qo‘shilishi sitokinlar kaskadida jiddiy transformatsiyalarni keltirib chiqaradi va patogenetik zanjirni izdan chiqaradi. Komorbidlik shakllanishining asosiy immunopatologik markerlari - gamma-interferon (IFN-γ), interleykin-12 (IL-12) va o‘sma nekrozi omili-alfa (TNF-α) ko‘rsatkichlarining bemorlar qonidagi dinamikasi va ularning o‘zaro patogenetik bog‘liqligini tahlil qilish juda dolzarb hisoblanadi. Ilmiy ishning maqsadi: Ushbu tadqiqotning maqsadi TB bilan kasallangan bemorlarda QDning epidemiologiyasi, xavf omillari va immunologik jihatlarini o‘rganish, shuningdek, ularni davolash va profilaktika qilish yondashuvlarini ishlab chiqishdan iborat. Ushbu maqsadni amalga oshirish uchun quyidagi vazifa qo‘yilgan: Sil kasalligiga chalingan ikkinchi tur qandli diabet bilan komorbid bemorlarda qondagi sitokinlar profilining (IFN-γ, IL-12, TNF-α) o‘zgarishlarini o‘rganish. Tadqiqotning obyekti: Qandli diabet bo‘yicha turli maqomga ega bo‘lgan sil kasalligiga chalingan bemorlar. QD bilan kasallangan bemorlarda TB xavfining asosiy omillari aniqlanadi va ularni stratifikatsiya qilish tizimi taklif etiladi.

References

1. Caceres, G., Calderon, R., & Ugarte-Gil, C. (2022). Tuberculosis and comorbidities: Treatment challenges in patients with comorbid diabetes mellitus and depression. Ther Adv Infect Dis. https://doi.org/10.1177/20499361221095831

2. Paik, S., & Yang, M. (2020). Suh H-W., Jo E-K. The roles of chemokines in immune response to mycobacterial infection. J Bacteriol Virol. https://doi.org/10.4167/jbv.2020.50.4.203

3. Pavan Kumar N., Nair D., Banurekha V.V., Dolla C., Kumaran P., Sridhar R. et al. Type 2 diabetes mellitus coincident with pulmonary or latent tuberculosis results in modulation of adipocytokines. (2016). Cytokine. https://doi.org/10.1016/j.cyto.2015.12.026

4. Ugarte-Gil, C., Curisinche, M., Herrera-Flores, E., Hernandez, H., & Rios, J. (2021). Situation of the tuberculosisdiabetes comorbidity in adults in Peru: 2016-2018. Rev Peru Med Exp Salud Publica.

5. doi: 10.17843/rpmesp.2021.382.6764. PMID: 34468572. PubMed

6. Jarde, A., Romano, E., Afaq, S., Elsony, A., Lin, Y., Huque, R., et al. (2022). Prevalence and risks of tuberculosis multimorbidity in low-income and middle-income countries: a meta-review. BMJ Open. https://doi.org/10.1136/bmjopen-2022-060906

7. Calderon, R. I., Arriaga, M. B., Aliaga, J. G., Barreda, N. N., Sanabria, O. M., et al. (2022). Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru. Int J Infect Dis. https://doi.org/10.1016/j.ijid.2022.01.012

8. Ugarte-Gil, C., & Moore, D. A. J. (2014). Tuberculosis and diabetes co-morbidity: an unresolved problem. Rev Peru Med Exp Salud Publica.

9. MacLean, E. L., Villa-Castillo, L., Ruhwald, M., Ugarte-Gil, C., & Pai, M. (2022). Integrated testing for TB and COVID-19. Med, (9). https://doi.org/10.1016/j.medj.2022.02.002

Downloads

Published

2026-09-26

How to Cite

1.
Xolmatova GA, Xalimova ZY, Jurayeva MA, Ashuraliyeva MA. TUBERKULEZ VA QANDLI DIABET BILAN KOMORBID HOLATDA TUR VA TUBERKULEZ BILAN BEMORLARDA IMMUNOLOGIK VA SITOKINLAR PROFILI MARKERLARINING PROGNOSTIK IMKONIYATLARINI ANIQLASH. TTI [Internet]. 2026 Sep. 26 [cited 2026 Nov. 18];2(9):291-5. Available from: https://tibbiyot-talimi-va-innovatsiyalari.uz/index.php/TTI/article/view/114
Vol. 2 No. 9 (2026): Journal of "Medical Education and Innovations"